tirzepatide for iih Efficacy of Dual GIP/GLP‐1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real‐World Propensity Score‐Matched Study - Azzam - 2025 - Endocrinology, Diabetes & Metabolism Idiopathic Intracranial Hypertension After Abrupt

This active comparator design was selected to ensure that all patients had similar motivations for weight management and shared comparable baseline characteristics, thus allowing for a more accurate comparison of outcomes

These changes correlate with improved metabolic health independent of weight loss magnitude

Understanding the realistic timeline prevents both premature disappointment and unrealistic expectations

Mediation analyses show that early (24week) declines are only modestly weightmediated (18%31%), whereas by 72 weeks the reductions are largely weightmediated (57%87%), indicating an initial partly weightindependent signal that becomes predominantly weightlinked with sustained treatment [34]

In this trial, tirzepatide at all three doses (5 mg, 10 mg, and 15 mg) achieved significantly greater weight loss compared to once weekly semaglutide 1 mg

The tirzepatide before and after data shows similar threshold effects at the 15% mark, reinforcing that this is a physiologically meaningful breakpoint across compound classes